A5049544471- Bone health and osteoporosis research
- Bone health and treatments
- Bone Metabolism and Diseases
- Bone and Joint Diseases
- Hip and Femur Fractures
- Vitamin D Research Studies
- Bone fractures and treatments
- Connective tissue disorders research
- Estrogen and related hormone effects
- Medical Imaging Techniques and Applications
- Hip disorders and treatments
- Rheumatoid Arthritis Research and Therapies
- MicroRNA in disease regulation
- Alkaline Phosphatase Research Studies
- Spondyloarthritis Studies and Treatments
- Pelvic and Acetabular Injuries
- Liver Disease Diagnosis and Treatment
- Shoulder Injury and Treatment
- Cytokine Signaling Pathways and Interactions
- Bariatric Surgery and Outcomes
- Liver Disease and Transplantation
- Glaucoma and retinal disorders
- Shoulder and Clavicle Injuries
- Folate and B Vitamins Research
- Liver Diseases and Immunity
Barmherzige Schwestern Krankenhaus Wien
2015-2025
Sigmund Freud University Vienna
2010-2025
Karl Landsteiner Society
2015-2025
Krankenhaus der Barmherzigen Schwestern Ried
2023
Krankenhaus der Elisabethinen
2023
Amt für Umwelt
2023
Deutscher Bundestag
2023
St Vincent Hospital
2000-2022
St Vincent Medical Center
2000-2022
Vienna General Hospital
2010-2022
Abstract The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for treatment postmenopausal women with osteoporosis. Participants who completed were eligible to enter an extension continue evaluation up 10 years. For results presented here, from group had 2 more years (long-term group) those placebo exposure (cross-over group). We report bone turnover markers (BTMs), mineral density (BMD), fracture rates, safety. A total 4550 enrolled in (2343 long-term;...
The Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) extension is evaluating the long-term efficacy and safety denosumab for up to 10 years.The objective study was report results from first 3 years extension, representing exposure.This a multicenter, international, open-label 4550 women.Women FREEDOM group received more total (long-term) women placebo (crossover).Bone turnover markers (BTMs), bone mineral density (BMD), fracture, data are...
Over 12 months, romosozumab increased bone formation and decreased resorption, resulting in mineral density (BMD) postmenopausal women with low BMD (NCT00896532). Herein, we report the study extension evaluating 24 months of treatment romosozumab, discontinuation alendronate followed by denosumab. Postmenopausal aged 55 to 85 years a lumbar spine (LS), total hip (TH), or femoral neck T-score ≤-2.0 ≥-3.5 were enrolled randomly assigned placebo, one five regimens (70 mg, 140 210 mg monthly...
Damage to cells and tissues is one of the driving forces aging age-related diseases. Various repair systems are in place counteract this functional decline. In particular, property adult stem self-renew differentiate essential for tissue homeostasis regeneration. However, their functionality declines with age (Rando, 2006). One organ that notably affected by reduced differentiation capacity skeleton. Here, we found circulating microvesicles impact on osteogenic mesenchymal a...
Context: Established bone turnover markers do not reflect fracture risk in idiopathic male and premenopausal osteoporosis the role of microRNAs (miRNAs) these patients is currently unclear. miRNAs are a class small non-coding RNAs that regulate gene expression tissue homeostasis. They considered new endocrine regulators with promising potential as biomarkers. Objective: Evaluation circulating miRNA signatures female subjects postmenopausal osteoporotic low-traumatic fractures. Design,...
Occupationally used high-frequency vibration is supposed to have negative effects on blood flow and muscle strength. Conversely, low-frequency as a training tool appears increase strength, but nothing known about its peripheral circulation. The aim of this investigation was quantify alterations in volume after whole vibration--after exercising the device Galileo 2000 (Novotec GmbH, Pforzheim, Germany). Twenty healthy adults performed 9-min standing test. They stood with both feet platform,...
Abstract The selective cathepsin K inhibitor odanacatib (ODN) progressively increased bone mineral density (BMD) and decreased bone-resorption markers during 2 years of treatment in postmenopausal women with low BMD. A 1-year extension study further assessed ODN efficacy safety the effects discontinuing therapy. In base study, BMD T-scores between −2.0 −3.5 at lumbar spine or femur received placebo 3, 10, 25, 50 mg weekly. After years, patients (n = 189) were rerandomized to weekly for an...
Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases density, and reduces fracture risk. This study evaluates the time course determinants of turnover marker (BTM) response during denosumab treatment, percentage denosumab-treated women with BTMs below premenopausal reference interval, correlations between changes in mineral density (BMD). The BTM substudy Fracture REduction Evaulation Denosumab Osteoporosis every 6 Months (FREEDOM) Trial...
ABSTRACT Laparoscopic Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are common effective methods to treat severe obesity, but these procedures can adversely influence bone metabolism areal mineral density (aBMD). This was a prospective 24-month single-center interventional two-arm study in 220 women similarly aged men (median age 40.7 years) with body mass index (BMI) >38 kg/m2 after RYGB SG procedures. Patients were randomized into: 1) an intervention group receiving:...
Odanacatib (ODN) is a selective inhibitor of the collagenase cathepsin K that highly expressed by osteoclasts. In this 2-year, phase 2, dose-ranging trial, postmenopausal women with bone mineral density (BMD) T-scores -2.0 to -3.5 at spine or hip were randomized weekly placebo ODN 3, 10, 25, 50 mg plus vitamin D(3) and calcium. Prespecified trial-extensions continued through 5 years. year all re-randomized placebo. For years 4 5, who received 3 in 1 2 mg; others treatments. Endpoints...
The role of sclerostin as a key regulator bone formation remains unknown after Roux-en-Y gastric bypass (RYGB) or laparoscopic sleeve gastrectomy (SG).The study objectives were evaluation and Dickkopf-1 (DKK-1) serum levels surgery correlations with turnover markers (P1NP, CTX), parathyroid hormone (iPTH) areal mineral density (BMD), changes at total body, lumbar spine hip.This was prospective observational single-center two-arm in premenopausal women acute adipositas over 24...
Persistence with and adherence to osteoporosis therapy are critical for fracture reduction. This non-interventional study is evaluating medication-taking behavior of women postmenopausal (PMO) receiving denosumab in Germany, Austria, Greece, Belgium. Patients were representative the PMO population highly persistent adherent at 12 months. important optimal treatment efficacy, namely ongoing, will evaluate routine practice four European countries. The enrolled who had been prescribed...
Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by periarticular bone loss and new formation. Current data regarding systemic mineral density (BMD) in PsA are conflicting. The aim of this study was to evaluate microstructure volumetric BMD (vBMD) patients with psoriasis. We performed HR-pQCT scans at the ultradistal radius 50 patients, 30 psoriasis 70 healthy, age- sex-related controls assessing trabecular volume (BV/TV), number (Tb.N), inhomogeneity network,...
The assessment of bone quality and the prediction fracture risk in idiopathic osteoporosis (IOP) are complex prospects as mineral density (BMD) turnover markers (BTM) do not indicate fracture-risk. MicroRNAs (miRNAs) promising new biomarkers for diseases, but current understanding biological information contained variability miRNAs is limited. Here, we investigated association between serum-levels 19 miRNA to microstructure histomorphometry based upon biopsies µCT (9.3 μm) scans from 36...
Abstract Increases in BMD are correlated with improvements 2D and 3D trabecular microarchitecture indices teriparatide treatment. Therefore, bone may be one of the mechanisms to explain how increases improve strength during Introduction: Bone is determined by other elements quality, including microarchitecture. Teriparatide treatment improves both cortical lumbar spine (LS) account for ∼30–41% vertebral fracture risk reduction The relationship between has not yet been studied. Materials...
Abstract During teriparatide (TPTD) treatment, high levels of bone formation are accompanied by an increase in resorption. The aim this work was to test if coadministration raloxifene (RAL) or alendronate (ALN) following 9 months ongoing TPTD therapy would reopen the anabolic window, thereby exerting additional benefit on mineral density (BMD). Postmenopausal women (n = 125) with severe osteoporosis treatment for were randomized into three open-label groups a further months: ALN (70 mg/week)...
Abstract Nine month teriparatide (TPTD) monotherapy followed by co-administration of raloxifene (RAL) or alendronate (ALN) for another nine 9 months resulted in incremental bone mineral density (BMD) increase. The aim this study was to investigate the effects continued antiresorptive treatments 12 extension phase. Postmenopausal women (n = 125) with severe osteoporosis on ongoing TPTD treatment were randomized into three open-label groups months: ALN (70 mg/week, n 41), RAL (60 mg/d, 37)...
Persistence with osteoporosis therapy is vital for fracture prevention. This non-interventional study of postmenopausal women receiving denosumab in Germany, Austria, Greece, and Belgium found that persistence remains consistently high after 24 months patients at risk fracture. Continued clinical practice evaluated medication-taking behavior factors influencing persistence. Subcutaneous (60 mg every 6 months) was assigned according to prescribing information local guidelines before...